Phase I study of ruxolitinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma.

Yasmeen Rauf; Rachel Hufsey; Kathy Robinson; John H. Suh; Samuel T. Chao; Erin Sennett Murphy; Jennifer S. Yu; David M. Peereboom; Manmeet Singh Ahluwalia; Wei Wei

doi:10.1200/JCO.2021.39.15_SUPPL.2060

Phase I study of ruxolitinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma.

Yasmeen Rauf, Rachel Hufsey, Kathy Robinson, John H. Suh, Samuel T. Chao, Erin Sennett Murphy, Jennifer S. Yu, David M. Peereboom, Manmeet Singh Ahluwalia, Wei Wei

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	39
DOIs	https://doi.org/10.1200/JCO.2021.39.15_SUPPL.2060
State	Published - May 28 2021

Disciplines

Medicine and Health Sciences
Oncology

Access to Document

10.1200/JCO.2021.39.15_SUPPL.2060License: Unspecified

Cite this

@article{7ec9a73a980347d79f266d4c76ca3b86,

title = "Phase I study of ruxolitinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma.",

author = "Yasmeen Rauf and Rachel Hufsey and Kathy Robinson and Suh, \{John H.\} and Chao, \{Samuel T.\} and Murphy, \{Erin Sennett\} and Yu, \{Jennifer S.\} and Peereboom, \{David M.\} and Ahluwalia, \{Manmeet Singh\} and Wei Wei",

note = "2060 Background: Ruxolitinib is a novel, potent, and selective inhibitor of JAK1 (Janus kinase 1) and JAK2 with modest to marked selectivity against TYK2 (tyrosine kinase 2) and JAK3, respectively. Ruxolitinib interferes with the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function.",

year = "2021",

month = may,

day = "28",

doi = "10.1200/JCO.2021.39.15\_SUPPL.2060",

language = "American English",

volume = "39",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Phase I study of ruxolitinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma.

AU - Rauf, Yasmeen

AU - Hufsey, Rachel

AU - Robinson, Kathy

AU - Suh, John H.

AU - Chao, Samuel T.

AU - Murphy, Erin Sennett

AU - Yu, Jennifer S.

AU - Peereboom, David M.

AU - Ahluwalia, Manmeet Singh

AU - Wei, Wei

N1 - 2060 Background: Ruxolitinib is a novel, potent, and selective inhibitor of JAK1 (Janus kinase 1) and JAK2 with modest to marked selectivity against TYK2 (tyrosine kinase 2) and JAK3, respectively. Ruxolitinib interferes with the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function.

PY - 2021/5/28

Y1 - 2021/5/28

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.2060

U2 - 10.1200/JCO.2021.39.15_SUPPL.2060

DO - 10.1200/JCO.2021.39.15_SUPPL.2060

M3 - Article

VL - 39

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Phase I study of ruxolitinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma.

Disciplines

Access to Document

Other files and links

Cite this